Horizon Therapeutics Public Limited Quick Ratio (HZNP) starting from the second quarter 2023 to second quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Horizon Therapeutics Public Limited Company  (NASDAQ: HZNP)

Horizon Therapeutics Public Limited's Quick Ratio

HZNP's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Horizon Therapeutics Public Limited's Cash & cash equivalent grew by 6.61 % in the Q2 2023 sequentially, faster than Current Liabilities, this led to improvement in Horizon Therapeutics Public Limited's Quick Ratio to 2.69, above Horizon Therapeutics Public Limited Company average Quick Ratio.

Within Major Pharmaceutical Preparations industry 348 other companies have achieved higher Quick Ratio than Horizon Therapeutics Public Limited in second quarter 2023. While Quick Ratio total ranking in the second quarter 2023 has deteriorated compared to the prior quarter from 131 to 1343.

Explain Quick Ratio?
How much Cash & cash equivalents HZNP´s has?
What are HZNP´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

HZNP Quick Ratio (Jun 30 2023)
Q2		 (Mar 31 2023)
Q1		 (Dec 31 2022)
Q4		 (Sep 30 2022)
Q3		 (Jun 30 2022)
Q2
Y / Y Current Liabilities Change 16.01 % 7.24 % 3.85 % 0.77 % -7.24 %
Y / Y Cash & cash equivalent Change 30.15 % 40.62 % 48.82 % 99.11 % 132.47 %
Quick Ratio MRQ 2.69 2.62 2.48 2.48 2.4
HZNP's Total Ranking # 1343 # 131 # 1159 # 1263 # 1301
Seq. Current Liabilities Change 3.71 % -7.05 % 10.61 % 8.79 % -4.13 %
Seq. Cash & cash equivalent Change 6.61 % -1.75 % 10.41 % 12.54 % 15.18 %



Quick Ratio second quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 349
Healthcare Sector # 607
Overall Market # 1343


Quick Ratio Statistics
High Average Low
4.21 1.9 0.19
(Dec 31 2019)   (Jun 30 2011)




Financial Statements
Horizon Therapeutics Public Limited's Current Liabilities $ 918 Millions Visit HZNP's Balance sheet
Horizon Therapeutics Public Limited's Cash & cash equivalent $ 2,469 Millions Visit HZNP's Balance sheet
Source of HZNP's Sales Visit HZNP's Sales by Geography


Cumulative Horizon Therapeutics Public Limited's Quick Ratio

HZNP's Quick Ratio for the trailling 12 Months

HZNP Quick Ratio

 (Jun 30 2023)
12 Months		 (Mar 31 2023)
12 Months		 (Dec 31 2022)
12 Months		 (Sep 30 2022)
12 Months		 (Jun 30 2022)
12 Months
Y / Y Current Liabilities TTM Growth 6.74 % 1.15 % 11.61 % 25.31 % 46.31 %
Y / Y Cash & cash equivalent TTM Growth 49.63 % 70.05 % 87.43 % 51.73 % 13.91 %
Quick Ratio TTM 2.57 2.5 2.34 2.14 1.83
Total Ranking TTM # 3940 # 740 # 538 # 3946 # 3999
Seq. Current Liabilities TTM Growth 3.63 % 1.74 % 1.04 % 0.19 % -1.79 %
Seq. Cash & cash equivalent TTM Growth 6.57 % 8.33 % 10.65 % 17.14 % 21.12 %

Quick ratio ranking by company, industry and sector >> Back to HZNP Financial Strength Comparisons >> Go to Compare HZNP Quick Ratio to its Competitors

On the trailing twelve months basis HZNP Cash & cash equivalent grew by 30.15 % in Q2 2023 year on year, faster than Current Liabilities, this led to increase in in Horizon Therapeutics Public Limited's Quick Ratio to 2.57, above HZNP average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 539 other companies have achieved higher Quick Ratio than Horizon Therapeutics Public Limited. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2023 from 740 to 3940.

Explain Quick Ratio?
How much Cash & cash equivalents HZNP´s has?
What are HZNP´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 540
Healthcare Sector # 1081
Within the Market # 3940


trailing twelve months Quick Ratio Statistics
High Average Low
2.57 1.44 0.85
(Jun 30 2023)   (Sep 30 2017)




Companies with similar Quick Ratio in the quarter ending Jun 30 2023, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2023 MRQ Cash & cash equivalentJun 30 2023 MRQ Current Liabilities
Capricor Therapeutics inc   7.36 $ 37.793  Millions$ 5.134  Millions
Arcutis Biotherapeutics Inc   7.33 $ 268.671  Millions$ 36.659  Millions
Prf Technologies Ltd   7.32 $ 6.162  Millions$ 0.842  Millions
Marinus Pharmaceuticals Inc   7.29 $ 175.336  Millions$ 24.047  Millions
Metavia Inc   7.20 $ 28.688  Millions$ 3.983  Millions
Bolt Biotherapeutics Inc   7.14 $ 125.866  Millions$ 17.618  Millions
Clearside Biomedical Inc   7.12 $ 35.005  Millions$ 4.915  Millions
Cormedix Inc   7.09 $ 52.401  Millions$ 7.387  Millions
Puretech Health Plc  7.05 $ 362.261  Millions$ 51.370  Millions
Opus Genetics Inc   6.94 $ 39.999  Millions$ 5.761  Millions
Theravance Biopharma inc   6.82 $ 167.451  Millions$ 24.546  Millions
Ngm Biopharmaceuticals Inc   6.81 $ 193.544  Millions$ 28.423  Millions
Oragenics Inc   6.81 $ 6.474  Millions$ 0.951  Millions
Sagimet Biosciences inc   6.80 $ 18.508  Millions$ 2.723  Millions
Assembly Biosciences Inc   6.78 $ 59.831  Millions$ 8.831  Millions
Calcimedica Inc   6.77 $ 19.084  Millions$ 2.817  Millions
Hoth Therapeutics Inc   6.74 $ 11.569  Millions$ 1.716  Millions
Context Therapeutics Inc   6.70 $ 25.138  Millions$ 3.750  Millions
Abcellera Biologics Inc   6.69 $ 795.694  Millions$ 118.905  Millions
Cohbar Inc   6.57 $ 12.311  Millions$ 1.874  Millions
Carisma Therapeutics Inc   6.51 $ 117.078  Millions$ 17.973  Millions
Ardelyx inc   6.50 $ 255.158  Millions$ 39.226  Millions
Chinook Therapeutics Inc   6.50 $ 297.165  Millions$ 45.704  Millions
Tff Pharmaceuticals Inc  6.31 $ 7.663  Millions$ 1.215  Millions
Sol gel Technologies Ltd   6.27 $ 36.563  Millions$ 5.835  Millions
Incannex Healthcare Inc  6.25 $ 55.483  Millions$ 8.877  Millions
Marker Therapeutics inc   6.20 $ 18.122  Millions$ 2.921  Millions
Gracell Biotechnologies Inc   6.13 $ 163.833  Millions$ 26.728  Millions
Immunogen inc   6.10 $ 571.987  Millions$ 93.702  Millions
Neuphoria Therapeutics Inc   6.10 $ 25.184  Millions$ 4.129  Millions

Date modified: 2026-09-12T06:14:33+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.